2020 Volume 36 Issue 2 Pages 133-142
Background: We aimed to study the efficacy and safety of transcatheter closure of the ductus among neonates and young infants with patent ductus arteriosus (PDA).
Patients and Methods: Of 25 subjects with PDA, we compared the adverse events in 15 patients who underwent transcatheter closure and 10 patients who underwent surgical closure.
Results: Age (115 days, range 6–212) and weight (4.20 kg, 1.62–8.79) at procedure, pulmonary to systemic flow ratio (3.54, 1.06–8.08), mean pulmonary arterial pressure (28 mmHg, 12–60), and ductal diameter (4.3 mm, 1.1–8.8) did not significantly differ between the groups. Within the transcatheter closure group, we used Amplatzer™ Duct Occluder (ADO) in 8, ADO-II in 1, and Amplatzer™ Vascular Plug-II (AVP-II) in 6 patients. Complete occlusions were attained in all but 2 patients, following successful surgical closure. There were 4 major adverse events in the transcatheter closure group (1 device migration, 2 transfusions, 1 pneumonia) and 3 major adverse events in the surgical closure group (1 chylothorax, 1 respiratory failure, 1 coarctation), which did not differ between the groups. There were no deaths related to either procedure.
Conclusions: transcatheter closure is feasible, but the risks of major adverse events were noteworthy.
